AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

In this article, check out the latest information on EA FC 26 Wonderkids. The best young talents to scout in FC 26 career ...